NBIX — Neurocrine Biosciences, Inc.
$167.40
$-2.00 (-1.18%)
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.
Market Cap
$16.94B
Forward P/E
13.6x
52-Week Range
N/A
NBIX Price History
Revenue vs. Net Income
$2.9B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$749M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
16.4%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
3.4x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
1.2%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-1.2%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
